Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Mersana Therapeutics, Inc. Common Stock (MRSN)

Pharmaceutical Preparations

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

840 MEMORIAL DRIVE
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/28/2017

Market Cap

161,317,625

Shares Outstanding

120,580,000

Weighted SO

120,582,114

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

TERN --.--%

AMLX --.--%

ABOS --.--%

INZY --.--%

XFOR --.--%

DAWN --.--%

HOOK --.--%

THRX --.--%

CGEM --.--%

Beta

1.5270

Last Div

0.0000

Range

1.065-6.28

Chg

-0.1750

Avg Vol

1407661

Mkt Cap

161317625

Exch

NASDAQ

Country

US

Phone

617 498 0020

DCF Diff

2.5180

DCF

-1.2080

Div Yield

0.0000

P/S

5.3886

EV Multiple

-1.2584

P/FV

18.9479

Div Yield %

0.0000

P/E

-1.5240

PEG

-0.0457

Payout

-0.0022

Current Ratio

2.7171

Quick Ratio

2.7171

Cash Ratio

0.9488

DSO

19.1419

DIO

0.0000

Op Cycle

19.1419

DPO

646.9088

CCC

-627.7670

Gross Margin

0.9432

Op Margin

-3.6027

Pretax Margin

-3.4998

Net Margin

-3.4998

Eff Tax Rate

-0.0048

ROA

-0.5849

ROE

-3.3391

ROCE

-0.9223

NI/EBT

1.0000

EBT/EBIT

0.9715

EBIT/Rev

-3.6027

Debt Ratio

0.1621

D/E

3.4456

LT Debt/Cap

0.6692

Total Debt/Cap

0.7751

Int Coverage

-2157.0600

CF/Debt

-4.6405

Equity Multi

21.2564

Rec Turnover

19.0682

Pay Turnover

0.5642

Inv Turnover

0.0000

FA Turnover

3.2586

Asset Turnover

0.1671

OCF/Share

-1.1097

FCF/Share

-1.1178

Cash/Share

1.3403

OCF/Sales

-4.5008

FCF/OCF

1.0073

CF Coverage

-4.6405

ST Coverage

-11.2406

CapEx Coverage

-136.1020

Div&CapEx Cov

-110.7157

P/BV

18.9479

P/B

18.9479

P/S

5.3886

P/E

-1.5240

P/FCF

-1.1885

P/OCF

-1.1850

P/CF

-1.1850

PEG

-0.0457

P/S

5.3886

EV Multiple

-1.2584

P/FV

18.9479

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 01, 16:30 Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Oct 31, 16:30 Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Revenue Product Segmentation